GHRP-2

What GHRP-2 Does

GHRP-2 (Growth Hormone Releasing Peptide-2, also known as pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that produces the strongest sustained GH release of any GHRP currently available. Developed through the same research lineage as GHRP-6 by Cyril Bowers and colleagues, GHRP-2 was optimized for greater GH-releasing potency while reducing the severe appetite spike that characterizes GHRP-6. It occupies the pharmacological middle ground between the ultra-clean Ipamorelin and the appetite-heavy GHRP-6.

GHRP-2 holds a distinction among GHRPs: it was approved in Japan as pralmorelin (trade name GHRP Kaken 100) for diagnostic testing of growth hormone deficiency. This gives it more formal clinical validation than most research peptides in this class.

The mechanisms that matter:

• GHS-R1a (ghrelin receptor) agonism — like all GHRPs, GHRP-2 binds the ghrelin receptor on pituitary somatotrophs to trigger GH release. However, GHRP-2 has been shown in head-to-head studies to produce higher peak GH levels than GHRP-6 or Ipamorelin at equivalent doses. This is its defining pharmacological advantage
• Moderate appetite stimulation — GHRP-2 activates hypothalamic ghrelin signaling but with less intensity than GHRP-6. Users describe a noticeable increase in appetite that is manageable, not the overwhelming hunger that GHRP-6 produces. This makes GHRP-2 compatible with body recomposition protocols where some appetite increase is tolerable
• Mild cortisol and prolactin elevation — GHRP-2 stimulates ACTH (increasing cortisol) and prolactin release, but less aggressively than Hexarelin or even GHRP-6 at equivalent doses. At 100 mcg, these elevations are transient and typically clinically insignificant. At 200–300 mcg, they become more relevant
• Synergy with GHRH analogs — GHRP-2 paired with CJC-1295 (a GHRH analog) produces the strongest synergistic GH release of any GHRP + GHRH combination. The dual-receptor activation (ghrelin receptor + GHRH receptor) amplifies GH output 3–5x beyond either agent alone
• Minimal desensitization — unlike Hexarelin, which shows receptor desensitization within 2–4 weeks, GHRP-2 maintains its GH-releasing efficacy throughout standard 8–12 week cycles

GHRP-2 vs Other GH Secretagogues

Feature	GHRP-2	GHRP-6	Ipamorelin	Hexarelin	MK-677
GH release potency	Strongest (sustained)	Strong	Moderate	Very strong (single dose)	Moderate
Appetite effect	Moderate increase	Severe increase	Minimal	Mild increase	Moderate–strong
Cortisol elevation	Mild	Mild–moderate	None	Significant	None
Prolactin elevation	Mild	Mild	None	Significant	None
Desensitization	Low	Low	Low	High (2–4 weeks)	None
Route	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection	Oral
Best for	Max GH with moderate sides	Bulking, appetite	Clean GH, anti-aging	Short-term max pulse	Oral convenience

When to choose GHRP-2: You want the strongest possible GH release from a GHRP and are willing to accept moderate appetite stimulation and mild hormonal side effects. GHRP-2 is the “performance” GHRP — maximum output with acceptable trade-offs. It is the best choice for body recomposition, muscle growth, and recovery when Ipamorelin’s GH output feels insufficient.

When to choose Ipamorelin instead: You prioritize a clean side effect profile over maximum GH output. If you’re using GH peptides for anti-aging, sleep, or general wellness, Ipamorelin’s zero-cortisol, zero-prolactin profile is more appropriate.

When to choose GHRP-6 instead: You specifically want appetite stimulation as a feature (bulking, hard-gaining, post-illness recovery). GHRP-6’s appetite effect is uniquely powerful.

Dosing Protocol

Standard Protocol (With CJC-1295)

Parameter	Detail
Dose	100 mcg GHRP-2 + 100 mcg CJC-1295 (no DAC) per injection
Frequency	2–3 times daily
Best timing	Morning (fasted), post-workout, pre-sleep
Cycle length	8–12 weeks on, 4 weeks off
Route	Subcutaneous injection

The pre-sleep dose is the highest-value injection. It amplifies the natural nocturnal GH surge, producing the largest GH pulse of the day. If you can only inject once daily, do it 30 minutes before bed on an empty stomach.

Dose Tiers

Level	GHRP-2 Dose	GH Output	Side Effect Profile
Conservative	100 mcg, 1–2x daily	Strong	Minimal appetite, negligible cortisol/prolactin
Standard	100 mcg, 3x daily	Very strong	Moderate appetite, mild cortisol/prolactin
Aggressive	200 mcg, 2–3x daily	Near maximum	Noticeable appetite, measurable cortisol/prolactin
Maximum	300 mcg, 2–3x daily	Diminishing returns	Strong appetite, meaningful cortisol/prolactin

100 mcg is the sweet spot. GHRP-2’s GH release follows a saturation curve — going from 100 to 200 mcg provides maybe 30–40% more GH output, but the appetite, cortisol, and prolactin effects scale more linearly. The 100 mcg dose, especially paired with CJC-1295, provides excellent GH elevation with a manageable side effect profile.

Fasting Requirements

Critical for all GH peptides:

• Fast 2+ hours before injection — insulin directly suppresses pituitary GH release. A fed state can blunt the GH pulse by 50% or more
• Wait 30–60 minutes after injection before eating — allow the GH pulse to peak and begin clearing
• GHRP-2’s appetite effect makes the waiting period moderately challenging — less so than GHRP-6, but noticeable. The pre-sleep dose is the easiest for fasting compliance
• No carbs are the biggest concern — carbohydrates produce the strongest insulin response. If you must have something, a small amount of protein has less impact than carbohydrate

GHRP-2 Alone (Without CJC-1295)

Parameter	Detail
Dose	150–300 mcg per injection
Frequency	2–3 times daily
Cycle length	8–12 weeks on, 4 weeks off

GHRP-2 alone produces the strongest standalone GH pulse of any single GHRP. However, adding CJC-1295 still amplifies the response significantly through dual-receptor activation. The combination is recommended for optimal results.

Reconstitution

For a 5 mg vial of GHRP-2 — add 2.5 mL bacteriostatic water:

Dose	Volume to Draw
100 mcg	5 units on insulin syringe
150 mcg	7.5 units
200 mcg	10 units
300 mcg	15 units

Concentration: 2,000 mcg/mL. One 5 mg vial provides 50 doses at 100 mcg — roughly 17–25 days at 2–3 doses per day.

Combining with CJC-1295: Draw GHRP-2 first, then draw CJC-1295 from its vial into the same syringe. Inject immediately. Never pre-mix reconstituted peptides for long-term storage.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. Unreconstituted lyophilized powder can be frozen for long-term storage.

Cycling

• Standard: 8–12 weeks on, 4 weeks off
• Rationale: The off-cycle period allows cortisol and prolactin levels to fully normalize, prevents any potential receptor accommodation, and lets you assess results without ongoing peptide influence
• Off-cycle bridge: MK-677 (oral) can maintain some GH elevation during the off period — see the MK-677 Protocol. Be aware that MK-677 has its own appetite stimulation
• Blood work: If running aggressive doses (200–300 mcg), check prolactin and cortisol mid-cycle and compare to baseline. If prolactin is meaningfully elevated, reduce dose or discontinue

What to Expect

Realistic Timeline

• Week 1: Sleep quality improves — deeper sleep, easier waking, more vivid dreams. Moderate appetite increase begins after each injection. No visible body composition changes
• Weeks 2–3: Recovery from training noticeably faster. Muscle soreness duration decreases. Skin may appear slightly fuller (early water retention from GH elevation). Appetite effects become predictable and manageable
• Weeks 4–6: Body composition begins shifting. Users in a training program notice improved muscle tone and modest fat reduction. Skin quality improves (GH drives collagen synthesis). Nail growth often accelerates
• Weeks 6–8: Visible body recomposition for consistent trainers. Strength and endurance improvements. Recovery between sessions is markedly improved. Hair and skin quality continue improving
• Weeks 8–12: Maximum benefits from the cycle. Lean mass gains are established. Fat loss is measurable (especially in caloric deficit or maintenance). Transitioning off reveals which benefits were GH-dependent vs habit-dependent

Optimizing GHRP-2 Results

1. Train hard — GH amplifies recovery and adaptation. Without a training stimulus, body composition benefits are modest
2. Adequate protein — GH elevation increases protein synthesis. Aim for 1.6–2.2 g/kg body weight to maximize the anabolic signal
3. Sleep consistency — the pre-sleep GHRP-2 dose amplifies nocturnal GH. Disrupted sleep undermines the largest GH pulse of the day
4. Manage the appetite — GHRP-2’s appetite increase is moderate. If cutting, plan meals to follow the 30-minute post-injection fasting window so you satisfy the hunger with a controlled meal rather than snacking

What the Research Says

GHRP-2 has robust clinical validation, including regulatory approval in Japan:

Japanese approval (Pralmorelin): GHRP-2 was approved in Japan in 2004 as a diagnostic agent for growth hormone deficiency under the name pralmorelin (trade name GHRP Kaken 100). The diagnostic protocol involves 100 mcg IV administration followed by serial GH measurements over 120 minutes. This regulatory approval provides formal clinical safety data that most GHRPs lack. Published approval data in Endocrine Journal.

Head-to-head GHRP comparisons: Comparative pharmacological studies demonstrated that GHRP-2 produces higher peak serum GH concentrations than GHRP-6 at equivalent doses in healthy human subjects. Bowers et al. showed peak GH levels of 50–80 ng/mL with GHRP-2 (1 mcg/kg IV) vs 30–60 ng/mL with GHRP-6 at the same dose. Published in Journal of Clinical Endocrinology & Metabolism.

Synergy with GHRH: Arvat et al. demonstrated that the combination of GHRP-2 and GHRH produced synergistic GH release exceeding the sum of individual effects by 2–3 fold. This synergy was more pronounced than with other GHRPs, establishing GHRP-2 + GHRH as the highest-output non-exogenous GH protocol. Published in European Journal of Endocrinology.

Cortisol and prolactin data: Rigorous endocrine profiling showed that GHRP-2 at 1 mcg/kg produces transient, modest increases in cortisol and prolactin that peak at 30–60 minutes and return to baseline within 2–3 hours. At standard subcutaneous doses of 100 mcg, these elevations are typically within physiological range and do not produce clinical symptoms. Higher doses (2–3 mcg/kg) produce more substantial elevations. Published in Hormone Research.

Body composition research: While no large Phase 3 trials exist for GHRP-2 as a body composition agent, multiple smaller studies in GH-deficient and elderly populations demonstrated that GHRP-2-induced GH elevation produces measurable improvements in lean mass, fat mass, and functional capacity. The effects are consistent with what would be expected from sustained physiological GH elevation.

Derek (More Plates More Dates) has discussed GHRP-2 as the strongest GHRP option for users who find Ipamorelin’s GH output insufficient and want to avoid GHRP-6’s extreme appetite. He notes the Japanese clinical approval as a point of validation that most GHRPs cannot claim.

Andrew Huberman has discussed the ghrelin receptor system on the Huberman Lab podcast, explaining how GHRP-mediated GH release through the ghrelin pathway is pharmacologically distinct from GHRH-mediated release — and why the combination of both pathways produces synergistic output.

Safety

Common Side Effects

Side Effect	Frequency	Notes
Moderate appetite increase	~50%	Less intense than GHRP-6, manageable for most users
Water retention	~30%	Mild, indicates GH elevation. Resolves over cycle or post-cycle
Numbness/tingling	~15%	Carpal tunnel-like symptoms. Dose-dependent. Reduce dose if persistent
Cortisol elevation	~15% (at >100 mcg)	Mild and transient at standard doses. Monitor at aggressive doses
Prolactin elevation	~10% (at >100 mcg)	Mild. Risk increases with dose and duration
Injection-site reaction	~10%	Minor redness, soreness. Rotate injection sites
Headache	~8%	Usually mild, most common in first week
Dizziness	~5%	Transient, typically fasting-related

Critical Warnings

Prolactin monitoring at high doses. If running GHRP-2 at 200+ mcg per dose for extended cycles, check prolactin levels. Chronically elevated prolactin can suppress testosterone production and, in extreme cases, cause gynecomastia or galactorrhea. If prolactin is elevated, reduce dose or discontinue.

Cortisol awareness. While mild at standard doses, chronic cortisol elevation from aggressive GHRP-2 dosing undermines the very recovery and body composition goals you are pursuing. More is not better — stay at 100 mcg per dose for the optimal benefit-to-side-effect ratio.

Fasting is mandatory. Injecting in a fed state wastes the peptide. Insulin suppresses GH release at the pituitary level.

Not FDA-approved (outside of Japanese diagnostic use). GHRP-2 is approved in Japan as a diagnostic agent (pralmorelin) but is not approved for therapeutic use in any jurisdiction. All body composition and performance use is experimental.

Banned by WADA. GHRP-2 is specifically listed as a prohibited substance by WADA under the S2 category. Tested athletes cannot use GHRP-2.

Cancer precaution. GH promotes cell growth. Do not use with active malignancies, recent cancer history, or significant cancer risk factors.

Do Not Use If

• Active cancer or tumor history
• Active acromegaly or pituitary tumors
• History of prolactin-sensitive conditions (prolactinoma, galactorrhea)
• Uncontrolled diabetes (GH reduces insulin sensitivity)
• Pregnant or breastfeeding
• Under 18 (active growth plates)
• Subject to WADA/USADA testing

What Comes Next

• Pair with CJC-1295 in the Growth Hormone Stack — the gold standard GH combination
• Compare all GH peptides — Growth Hormone Peptides Compared for a comprehensive breakdown
• Want a cleaner profile? — Ipamorelin Protocol for zero cortisol and prolactin
• Need more appetite stimulation? — GHRP-6 Protocol if appetite is the goal
• Oral option — MK-677 Protocol for needle-free GH elevation
• Use the Reconstitution Calculator for exact unit counts